EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Tobacco, electronic nicotine delivery system, nicotine replacement therapy, and cannabinoid use during pregnancy: A descriptive cross-sectional survey

Sreemanjari Kandhasamy iD, Stéphanie Baggio, Jérôme Mathis, Yolanda Mattmann, Emeline Maisonneuve, Reto Auer, Alice Panchaud, Stephen P Jenkinson iD, Anna Schoeni iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0332961 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift PLOS One, 2025. Verfasst von Sreemanjari Kandhasamy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Electronic Nicotine Delivery Systems, Smoking Cessation, Cannabinoids, Tobacco Use Cessation Devices. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Investigator Initiated Clinical Trial (IICT) grant from the Swiss National Science Foundation (SNSF), Swiss Tobacco Prevention Fund (TPF), Swiss Cancer Research (SCR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tobacco smoking is associated with adverse health outcomes for both pregnant women and their offspring. Smoking cessation counseling is an effective method to help women quit smoking. Developing a targeted smoking cessation intervention could benefit those who struggle to quit tobacco and potentially reduce the harm due to any co-occurring tobacco use. Assessing the prevalence of tobacco, electronic nicotine delivery systems (ENDS), nicotine replacement therapy (NRT), and cannabinoid use in pregnancy is key to developing such interventions. Thus, we aimed to assess the prevalence and patterns of tobacco, ENDS, NRT, and cannabinoid use in pregnancy. We further aimed to assess the prevalence of smoking cessation counseling intervention. Materials and methods We conducted a cross-sectional survey among pregnant women attending regular clinical visits at Spitalzentrum Biel between February and May 2023 (n = 262). Frequency and proportion along with 95% confidence intervals (CI) were reported for tobacco, ENDS, NRT, and cannabinoid use in pregnancy.

Results

Tobacco use was reported among 7.6% (20/262, 95% CI: 4.2%−11.1%) of the included pregnant women. Tobacco cigarettes (conventional or roll-on) were used by 7.3% (19/262, 95% CI: 3.8%−10.7%) of the surveyed pregnant women, with 0.8% (2/262, 95% CI: 0.0%−3.4%) of them reporting use of cigarettes along with ENDS and 0.4% (1/262, 95% CI: 0.0%−3.8%) reporting use of the cigarettes with NRT. Cannabinoid use was reported by 3.8% (10/262, 95% CI: 1.1%−7.0%) of pregnant women and all of them used products with Cannabidiol (CBD) only. Additionally, only 25% (5/20, 95% CI: 10.0%−48.3%) of tobacco users had received smoking cessation counseling intervention.

Conclusion

The estimated prevalence of tobacco, ENDS, NRT, and cannabinoid use among the pregnant women in this survey was 7.6%, 0.8%, 0.4%, and 3.8% respectively. However, among tobacco users, only one-fourth received smoking cessation counseling intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Electronic Nicotine Delivery SystemsSmoking CessationCannabinoidsTobacco Use Cessation DevicesHumansFemalePregnancyCross-Sectional StudiesAdultYoung AdultPregnancy ComplicationsPrevalenceSurveys and QuestionnairesNicotine Replacement Therapy

Substanzen

Cannabinoids

Autor:innen und Institutionen

  • Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
  • Graduate School of Health Sciences, University of Bern, Bern, Switzerland.
  • Institute of Psychology, University of Lausanne, Lausanne, Switzerland.
  • Department of Obstetrics and Gynecology, Centre Hospitalier Bienne, Bienne, Switzerland.
  • Materno-Fetal and Obstetrics Research Unit, Department "Woman-Mother-Child", Lausanne University Hospital, Lausanne, Switzerland.
  • Center of Primary Care and Public Health (UNISANTÉ), University of Lausanne, Lausanne, Switzerland.

ORCID-Profile: Sreemanjari Kandhasamy, Stephen P Jenkinson, Anna Schoeni

Förderung

  • Investigator Initiated Clinical Trial (IICT) grant from the Swiss National Science Foundation (SNSF)
  • Swiss Tobacco Prevention Fund (TPF)
  • Swiss Cancer Research (SCR)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Kandhasamy, S., Baggio, S., Mathis, J., Mattmann, Y., Maisonneuve, E., Auer, R., Panchaud, A., Jenkinson, S. P., & Schoeni, A. (2025). Tobacco, electronic nicotine delivery system, nicotine replacement therapy, and cannabinoid use during pregnancy: A descriptive cross-sectional survey. PLOS One. https://doi.org/10.1371/journal.pone.0332961

Vancouver

Kandhasamy S, Baggio S, Mathis J, Mattmann Y, Maisonneuve E, Auer R, et al. Tobacco, electronic nicotine delivery system, nicotine replacement therapy, and cannabinoid use during pregnancy: A descriptive cross-sectional survey. PLOS One. 2025. doi:10.1371/journal.pone.0332961

BibTeX
@article{Kandhasamy2025,
  author = {Kandhasamy, Sreemanjari and Baggio, Stéphanie and Mathis, Jérôme and Mattmann, Yolanda and Maisonneuve, Emeline and Auer, Reto and Panchaud, Alice and Jenkinson, Stephen P and Schoeni, Anna},
  title = {Tobacco, electronic nicotine delivery system, nicotine replacement therapy, and cannabinoid use during pregnancy: A descriptive cross-sectional survey},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0332961}
}
Kostenlos starten →